Analysis Of Clinical Efficacy And Safety Of Levocarnitine Combined With Anti-heart Failure Drugs In The Treatment Of Chronic Heart Failure

Objective: To study the clinical efficacy and safety of levocarnitine combined with anti-heart failure drugs in the treatment of chronic heart failure.Methods: 120 patients with chronic heart failure were randomly divided into the treatment group of levocarnitine combined with anti-heart failure drugs(referred to as combined treatment group)and the treatment group of routine anti-heart failure treatment(referred to as control group),each group of 60 people,both of which present no statistically significant difference in patients’ medical history,gender and age.The control group was given with routine drug treatment for heart failure,including angiotensin converting enzyme inhibitors or angiotensin Ⅱ receptor blockers and beta blockers,diuretics and aldosterone receptor antagonists.While except the conventional drugs of heart failure,the combined treatment group was also applied with additional therapy of levocarnitine injection,150 m L 0.9% sodium chloride solution containing 2 g of levocarnitine at a static point,once a day for two weeks.Monitor the alterations before and after with corresponding drug therapy for both two groups,such as urine volume in 24 hours,B-type natriuretic peptide,six minute walking test,NYHA classification of cardiac function,left ventricular ejection fraction and heart failure score,and make a comprehensive evaluation for the efficacy of the drug.Moreover,to understand the safety of using levocarnitine in clinic,cardio-vascular adverse events and adverse reactions were also closely observed.Results: 1.Compared with the control group,some significant changes were observed after treatment with combined treatment group,including improvement on urine volume in 24 hours,decreased B-type natriuretic peptide,increased six minute walking test,obviously improved NYHA classification of cardiac function,increased left ventricular ejection fraction,in the heart failure score,dyspnea and lung rale improved significantly,the difference is statistically significant(P<0.05).2.Compared with the control group after treatment,the improvement of palpitations,edema in the heart failure score in the combination treatment group was not significantly improved after treatment,and the difference was not statistically significant(P>0.05).3.No significantly adverse reactions were found in the combined treatment group and the control group.Conclusions:1.In the study,the combined treatment group was better than the control group in improving urine volume in 24 hours,B-type natriuretic peptide,6-minute walking test,left ventricular ejection fraction,NYHA classification of cardiac function and heart failure score(dyspnea,lung rale).2.During the treatment of chronic heart failure,levocarnitine has no obviously adverse reactions,and its efficacy is worthy of affirmation,which can provide reference for clinical treatment.